Rise in exports boost Unichem Laboratories Q4 numbers

Indian pharma major, Unichem Laboratories posted a marginal growth QoQ but witnessed a threefold growth in its net profit YoY.  The stock closed 1.98 per cent down at Rs 262.70 on the day of results.

Company’s standalone revenues declined by 3.9 per cent to Rs 292.13 crore in Q4FY16 as against Rs 303.93 crore. Segment wise company’s total income from operations in India saw a drop of 9.3 per cent from 193.17 crore to crore Rs 175.09. However, foreign total operating income increased by 11.8 per cent to Rs 124.63 crore as against Rs 113.09 crore in the last quarter.

Company’s EBITDA too fell to Rs. 31.21 crores as against Rs. 34.09 crores a decrease of 8.4 per cent. Company’s net profits however, saw a rise of 37 per cent to Rs 28.15 crores as compared to Rs 20.54 crores in the previous quarter. Company saw a profit growth in the wake of tax benefit in Q4FY16.

Considering the year on year results, March quarter revenues had seen a rise of 16.6 per cent from Rs 250.56 crore in the same quarter last year. EBITDA saw a twofold rise of 110 per cent from Rs 14.82 crore in Q4FY15. Net profits gave a threefold rise from Rs 9.82 crore.

March 2016 closed on a positive note for Unichem Labs. Company’s consolidated revenues increased by 10.8 per cent to Rs. 1316.5 crore for the year ended March 2016 as compared to Rs 1187.71 crore for FY15. EBITDA surged at Rs. 163.9 crore for FY16 as compared to Rs 101.34 crore in FY15, an increase of 61.7 per cent. Net profit saw a growth of 43.3 per cent from Rs 75.39 crore in FY15 to Rs 108.03 crore in FY16.

Unichem Laboratories deals with the manufacturing and sale of active pharmaceutical ingredients (APIs) and formulations. The company offers its products in various therapeutic segments, such as cardiovascular, psychiatry, neurology, musculo-skeletal, gastro and anti-infective, among others. The company has plants in Ghaziabad, Roha, Goa, Baddi, Pithampur and Sikkim.